|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer.
|
31566309 |
2019 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients with BRAF (v-Raf murine sarcoma viral oncogene homolog B) V600E-mutated metastatic colorectal cancer (mCRC) have a poor prognosis.
|
30662270 |
2019 |
|
melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |
|
melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Accordingly, we evaluated the phenotypical and molecular changes of isogeneic human V600E BRAF-mutant melanoma cell line pairs pre- and post-treatment with vemurafenib.
|
31514305 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer.
|
30963570 |
2019 |
|
melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Sixty five consecutive formalin-fixed paraffin-embedded (FFPE) melanoma samples were prospectively tested for BRAF mutations with the VE1 (anti-BRAF V600E) antibody and for both BRAF and NRAS mutations with the Idylla NRAS-BRAF-EGFR S492R Mutation Assay cartridges.
|
31415669 |
2019 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.
|
31840683 |
2019 |
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |
|
melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here we assessed the role of urokinase type plasminogen activator receptor (uPAR) as a potentially valuable biomarker in the acquisition of BRAF-I resistance in V600E mutant melanoma cells.
|
30611716 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.
|
31672130 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Molecular alterations that predict response to treatment (eg, EGFR mutations, ALK rearrangements, ROS1 rearrangements, and BRAF V600E mutations) are present in approximately 30% of patients with non-small cell lung cancer.
|
31454018 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer.
|
31566309 |
2019 |
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer.
|
30963570 |
2019 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
A combination of encorafenib, cetuximab, and binimetinib resulted in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with the <i>BRAF</i> V600E mutation.
|
31566309 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report.
|
31250402 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Moreover, a 47-year-old female with a recurrent adenocarcinoma and a BRAF V600E mutation exhibited tumor regression after a fourth line therapy with dabrafenib and trametinib, targeting agents against BRAF mutations.
|
31440061 |
2019 |
|
melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Orthogonal partial least squares (O-PLS) predicted vemurafenib sensitivity with greater accuracy in both melanoma and non-melanoma BRAF-V600E cell lines than other leading machine learning methods, specifically Random Forests, Support Vector Regression (linear and quadratic kernels) and LASSO-penalized regression.
|
31672130 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Specifically, we will discuss current clinical applications of genomic information consisting of the use of the MAPK (mitogen-activated protein kinase) pathway genes <i>KRAS</i>, <i>NRAS</i>, and <i>BRAF</i> as prognostic and predictive biomarkers for standard treatment, risk stratification by primary tumor site and consideration of tumor laterality in patient selection for epidermal growth factor receptor (EGFR) antibody treatment, and the evaluation for genomic biomarkers, including <i>BRAF</i> V600E, <i>HER2</i> amplification, and gene rearrangements, for targeted therapies in clinical trials.
|
29911107 |
2018 |
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, we explored the effect of combined use of dabrafenib, a BRAF inhibitor, and cetuximab, an EGFR inhibitor, on BRAF(V600E)-mutant CRC stem cells and its possible mechanisms.
|
29534162 |
2018 |
|
melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30335711 |
2018 |
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
Colon cancers carrying BRAF V600E and β-catenin T41A activating mutations are resistant to numerous common anticancer drugs.
|
29541216 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
RNA-seq data was downloaded from the Gene Expression Omnibus (GEO) database for pre- and post-treatment tumor samples from three melanoma patients with EGFR-activating BRAF V600E mutations, and from The Cancer Genome Atlas (TCGA) melanoma database for tumor and non-tumor samples from patients with the BRAF V600E mutation and unknown EGFR activation status.
|
29387237 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Three of the four tumors had a BRAF (V600E) driver mutation, an EGFR (del E746-T751/S752V) driver mutation, or driver mutations in both EGFR (E709G) and KRAS (G12V).
|
29624782 |
2018 |